Patent · US Active

Drug based on maghemite for simultaneous reduction of gastrointestinal sodium resorption and phosphate resorption

US10632149B2 · kind B2 · utility

0Cited by

1References

2Claims

0Family size

Assignee

CHARITÉ—UNIVERSITÄTSMEDIZIN BERLIN · DE

Inventors

Susanne Wagner · Mittenwalde, DE
Matthias Taupitz · Teltow, DE
Joerg Schnorr · Oranienburg, DE
Monika Ebert · Teltow, DE
Nicola Stolzenburg · Berlin, DE
Janna Glaeser · Bremen, DE
Harald Kratz · Berlin, DE
Ralf Hauptmann · Berlin, DE
Janni Breinl · Chemnitz, DE
Angela Ariza De Schellenberger · Berlin, DE
Ines Gemeinhardt · Berlin, DE

Key dates

Filing date	Dec 28, 2015
Grant date	Apr 28, 2020
Priority date	—
Expiry date	Dec 28, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P13/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention includes a substance based on nanocrystalline maghemite having a crystal size of between 0.5 and 4 nm, which is defined by a proportion of divalent iron ions less than five percent by weight of the total iron, and the transport of sodium and simultaneously phosphate in the gastrointestinal wall from the gastrointestinal contents into the bloodstream is reduced and thus can improve the imbalance of electrolyte and water and mineral balances of patients having impaired renal function when used orally in combination with suitable pharmaceutical adjuvants.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.